Morishita Jintan Co., Ltd. (4524.T)
JPY 2065.0
(-0.24%)
JPY 2065.0
(-0.24%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -667 Million JPY | 64.37% |
| 2022 | -1.87 Billion JPY | -38.46% |
| 2021 | -1.35 Billion JPY | 3.7% |
| 2020 | -1.4 Billion JPY | -12.68% |
| 2019 | -1.24 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 56 Million JPY | 108.4% |
| 2023 Q2 | -1.31 Billion JPY | 22.52% |
| 2023 Q4 | -667 Million JPY | 19.93% |
| 2023 Q3 | -833 Million JPY | 36.8% |
| 2023 Q1 | -1.7 Billion JPY | 9.13% |
| 2023 FY | -667 Million JPY | 64.37% |
| 2022 Q2 | -1.62 Billion JPY | 0.0% |
| 2022 Q4 | -1.87 Billion JPY | -17.96% |
| 2022 Q3 | -1.58 Billion JPY | 2.28% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 1.22 Billion JPY | 154.449% |
| Takeda Pharmaceutical Company Limited | 4385.95 Billion JPY | 100.015% |
| Sumitomo Pharma Co., Ltd. | 389.83 Billion JPY | 100.171% |
| Shionogi & Co., Ltd. | -346.47 Billion JPY | 99.807% |
| Wakamoto Pharmaceutical Co.,Ltd. | -3.56 Billion JPY | 81.286% |
| Nippon Shinyaku Co., Ltd. | -42.15 Billion JPY | 98.418% |
| Kaken Pharmaceutical Co., Ltd. | -61.47 Billion JPY | 98.915% |
| Eisai Co., Ltd. | -97.93 Billion JPY | 99.319% |
| Hisamitsu Pharmaceutical Co., Inc. | -51.82 Billion JPY | 98.713% |
| Mochida Pharmaceutical Co., Ltd. | -32.92 Billion JPY | 97.974% |
| Fuso Pharmaceutical Industries,Ltd. | 7.6 Billion JPY | 108.774% |
| Nippon Chemiphar Co., Ltd. | 7.78 Billion JPY | 108.572% |
| Tsumura & Co. | 1.61 Billion JPY | 141.3% |
| Kissei Pharmaceutical Co., Ltd. | -44.16 Billion JPY | 98.49% |
| Torii Pharmaceutical Co., Ltd. | -34.43 Billion JPY | 98.063% |
| Towa Pharmaceutical Co., Ltd. | 172.7 Billion JPY | 100.386% |
| Fuji Pharma Co., Ltd. | 26.62 Billion JPY | 102.505% |
| Zeria Pharmaceutical Co., Ltd. | 28.98 Billion JPY | 102.301% |
| KYORIN Holdings, Inc. | 7.06 Billion JPY | 109.448% |
| Taiko Pharmaceutical Co.,Ltd. | 704 Million JPY | 194.744% |
| Daito Pharmaceutical Co.,Ltd. | 5.99 Billion JPY | 111.132% |
| SymBio Pharmaceuticals Limited | -6.51 Billion JPY | 89.765% |
| MedRx Co., Ltd | -1.72 Billion JPY | 61.221% |
| Mizuho Medy Co.,Ltd. | -8.71 Billion JPY | 92.348% |
| Solasia Pharma K.K. | -668 Million JPY | 0.15% |
| Modalis Therapeutics Corporation | -1.47 Billion JPY | 54.655% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | -7.25 Billion JPY | 90.804% |
| Sawai Group Holdings Co., Ltd. | 56.52 Billion JPY | 101.18% |
| Cyfuse Biomedical K.K. | -2.96 Billion JPY | 77.472% |
| Toho Holdings Co., Ltd. | -98.42 Billion JPY | 99.322% |
| Koa Shoji Holdings Co.,Ltd. | -11.12 Billion JPY | 94.007% |